Publication | Date | Description | Categories | Subcategories |
---|---|---|---|---|
(pdf 230.85 Kb)
|
Oct 2015
|
APLU submitted a letter to the Food and Drug Administration (FDA) expressing concern with potential changes to the international regulation of ketamine, as they would result in increased difficulty for biomedical researchers to use the drug for legitimate and appropriate treatments.
|
Categories
|
Subcategories
|
Stay Connected
X (formerly Twitter)
Facebook
YouTube
LinkedIn
RSS